Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918368 | 0.97 | SNCA (0.65) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Water SCHEMBL3422802 | 0.95 | SNCA (0.63) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Iodide SCHEMBL159922 | 0.95 | SNCA (0.63) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Bromide SCHEMBL163158 | 0.95 | SNCA (0.67) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL494 | 0.95 | SNCA (0.63) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Fluoride Ion SCHEMBL585089 | 0.95 | SNCA (0.63) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Bromide SCHEMBL8331435 | 0.92 | SNCA (0.64) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Fluoride Ion SCHEMBL6664234 | 0.92 | SNCA (0.61) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28828301 | 0.92 | SNCA (0.61) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11808415 | 0.92 | SNCA (0.61) | SNCAHIF1ACYP1A2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223604-B1 | Methods and kits for the detection of erythrocytes | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-05-29 | — | — | US | claimed |
| EP-2896609-B1 | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | RATIOPHARM GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-2807143-B1 | PROCESS FOR PREPARATION OF FINGOLIMOD | GLENMARK GENERICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| EP-2896609-A1 | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | ratiopharm GmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-9056813-B2 | Process for preparation of fingolimod | GLENMARK GENERICS LIMITED (IN) | 2015-06-16 | — | — | US | disclosed |
| EP-2807143-A2 | PROCESS FOR PREPARATION OF FINGOLIMOD | Glenmark Generics Limited (IN) | 2014-12-03 | — | — | EP | disclosed |
| US-8766005-B2 | Process for producing fingolimod salts | RATIOPHARM GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| WO-2013111162-A2 | PROCESS FOR PREPARATION OF FINGOLIMOD | GLENMARK GENERICS LIMITED (IN) | 2013-08-01 | — | — | WO | disclosed |
| US-20120184617-A1 | PROCESS FOR PRODUCING FINGOLIMOD SALTS | RATIOPHARM GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| EP-2456752-A2 | PROCESS FOR PRODUCING FINGOLIMOD SALTS | ratiopharm GmbH (DE) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009634-A2 | PROCESS FOR PRODUCING FINGOLIMOD SALTS | RATIOPHARM GMBH (DE) | 2011-01-27 | — | — | WO | disclosed |
| US-7223604-B1 | Methods and kits for the detection of erythrocytes | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184617-A1 | PROCESS FOR PRODUCING FINGOLIMOD SALTS | S1PR4, S1PR2, S1PR3 | SNCA 2186/4885HIF1A 3372/4885CYP1A2 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.